LABNasdaqPharmaceutical PreparationsFiscal year ends December 31

STANDARD BIOTOOLS INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.64+0.01 (+2.27%)

Close on Oct 19, 2026

Market cap: $251.45M
P/E (TTM): 2.9
Dividend yield: –

STANDARD BIOTOOLS INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	85	91	106	98	131	138	117	113	102	104	115	116	71	52	43	34	25
Cost of Revenue	43	46	56	61	–	–	53	51	50	46	43	0.30	0.30	0.30	0.10	12	11
Gross Profit	43	45	50	37	–	–	64	62	52	58	72	116	71	52	43	22	14
Research & Development	26	29	26	37	38	36	32	30	31	38	39	43	20	17	14	13	12
Selling, General & Admin	110	103	88	102	99	98	84	80	80	93	83	71	48	38	31	24	20
Advertising Expenses	2.20	2.60	2.00	3.90	3.40	1.60	3.40	2.20	1.80	2.30	2.90	4.20	2.40	1.30	0.70	0.50	–
Operating Expenses	153	172	127	153	198	189	169	161	110	132	–	–	–	–	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	161	160	178	165	168	90	70	61	48	43
Operating Income	-110	-127	-77	-116	-67	-51	-52	-48	-58	-73	-50	-52	-19	-18	-19	-15	-18
Interest Expense	–	–	4.57	4.33	3.82	3.57	4.28	14	5.82	5.82	5.81	5.34	0.01	0.63	3.10	2.16	2.88
Other Non-Operating Income	4.39	-5.01	1.39	-0.82	0.48	0.51	1.43	0.64	0.39	-1.17	-1.16	-0.86	0.50	-0.19	0.08	0.36	1.87
Merger & Restructuring Charges	15	13	7.08	9.73	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	–	–	–	0	0	0	0	0	0	0	0	0	0	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	-0.01	-0.21	-0.09	-0.14	-0.14	-0.09	-0.09	-0.08	-0.30	-0.03	0	0.01	0.10
Pretax Income	-97	-90	-74	-193	-64	-54	-67	-61	-64	-80	-55	-58	-16	-19	-22	-17	-19
Income Tax Expense	-38	0.54	0.45	-2.83	-4.42	-1.08	-1.92	-2.41	-3.26	-4.19	-1.48	-4.88	0.14	0.14	0.17	0.08	-0.05
Income from Continuing Operations	-59	-91	-75	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	-16	-48	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-75	-139	-75	-190	-59	-53	-65	-59	-61	-76	-53	-53	-17	-19	-22	-17	-19
Net Income to Common	-75	-185	-75	-190	–	–	–	–	–	–	–	–	-17	-19	-32	-17	-19
EPS (Basic)(per share)	-0.20	-0.52	-0.94	-2.43	-0.78	-0.74	-0.97	-1.49	-1.84	-2.62	-1.86	-1.90	-0.65	-0.86	-1.81	-8.94	-11.02
EPS (Diluted)(per share)	-0.20	-0.52	-0.94	-2.43	-0.78	-0.74	-0.97	-1.49	-1.84	-2.62	-1.86	-1.90	-0.65	-0.86	-1.81	-8.94	-11.02
Shares Outstanding (Basic, Weighted)(shares)	382	353	79	78	76	72	67	40	33	29	29	28	25	22	18	1.89	–
Shares Outstanding (Diluted, Weighted)(shares)	382	353	79	78	76	72	67	40	33	29	29	28	25	22	18	1.89	–
EBITDA	-101	-115	-73	-113	-64	-47	-47	-43	-51	-66	-45	-48	-16	-16	-17	-13	-16

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 50.5%
Operating margin: -112.8%
Net margin: 100.4%
Return on equity, FY2025: -16.7%

Financial strength

Current ratio: 9.10
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 475.4%

Valuation

P/E ratio: 2.9
Price to sales: 2.97
Price to book: 0.47
Dividend yield: –